Biresh Roy has resigned as CFO of Verona Pharma and a search has commenced for a successor. Meanwhile we continue to expect exciting data over the coming year from the company’s development of RPL554 in asthma, COPD and Cystic Fibrosis. Headline data from both the company’s Phase IIa trial of RPL554 in asthma and from a Phase IIa trial investigating the addition of RPL554 to standard reliever therapy in COPD is expected in H1 2016. We retain a positive stance.
